About Us

  Θ...Θ
Pharmews was founded in 2016, aiming to bring global pharma news here. Now we open a Chinese pharmaceutical news web for you.

Ceneal
Pharmews

Disclaimer: 

This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of pharmaceutical and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.

Popular posts from this blog

Shanghai Xunhe Pharma’s CDK4/6 Inhibitor XH-30002 IND Accepted by Chinese NMPA

Guideline on the Submission of Clinical Trial Data in China (2020.5 Draft for Public Review)

Drug Review Package of Chinese New Chemical or Biologic Drug